Page 12 - Regeneron Eylea News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AbbVie bets big on a gene therapy for eye diseases

AbbVie bets big on a gene therapy for eye diseases
biopharmadive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharmadive.com Daily Mail and Mail on Sunday newspapers.

United statesRoche lucentisNovarti beovuRegeneron eyleaDrug administrationDive briefCaribou biosciences

New data bolster Regeneron s plan to defend top-selling eye drug

New data bolster Regeneron s plan to defend top-selling eye drug
biopharmadive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharmadive.com Daily Mail and Mail on Sunday newspapers.

Novartis beovuDonald trumpGeoffrey porgesRegeneron eyleaDrug administrationDive briefPresident donald trump

Unity, on the rebound after catastrophe, shows promising results in early eye disease trial

Unity Biotechnology CEO Anirvan Ghosh, Ph.D. (Unity) Nearly a year after dropping its lead program and sinking its stock, Unity Biotechnology appears to be coming back on track with positive data in its phase 1 study in patients with advanced vascular eye disease. The anti-aging biotech said Tuesday its small-molecule inhibitor of Bcl-xL, a senolytic therapeutic, was well tolerated in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). Unity shares were up about 9% in early trading Tuesday morning. The study of UBX1325 was conducted in patients for whom anti–vascular endothelial growth factor (anti-VEGF) therapy was not considered to be beneficial anymore. Anti-VEGF treatments include Roche s Lucentis, Regeneron s Eylea, Novartis Beovu and Roche s Avastin.

United statesRoche lucentisRoche avastinAnirvan ghoshNovarti beovuJeffrey heierRegeneron eyleaRetina research at ophthalmic consultants of bostonVitreoretinal serviceUnity biotechnologyRetina researchOphthalmic consultantsஒன்றுபட்டது மாநிலங்களில்ஜெஃப்ரி ஹேஎர்விழித்திரை ஆராய்ச்சி இல் கண் ஆலோசகர்கள் ஆஃப் போஸ்டன்விதிறெோரேதினாள் சேவை

Stocks Making the Biggest Moves in the Premarket: Etsy, Uber, Zynga, Rocket Companies & More

Uber (UBER) – Uber lost 6 cents per share for its latest quarter, compared to expectations of a 54 cents a share loss. Revenue was below forecasts, however, and Uber indicated it would pay drivers more to get cars back in service as the economy rebounds. Uber fell 3.7% in premarket trading. Zynga (ZNGA) – Zynga earned 8 cents per share for the first quarter, a penny a share shy of estimates. The mobile game producer s revenue exceeded estimates and Zynga raised its full-year guidance on expectations of strong demand for its live gaming services. Its shares surged 5% in premarket action. Rocket Companies (RKT) – Rocket Companies reported quarterly earnings of 89 cents per share, in line with forecasts. Loan volume for the lender jumped during the quarter, but current-quarter guidance for the key metric of gain-on-sale margins is well below first-quarter levels. Its shares plummeted 13.6% in premarket trading.

United statesBecton dickinsonMichel doukerisCarlos britoRegeneron eyleaRegeneron pharmaceuticalsRocket companiesCruise lineWall streetChief financial officer andriel laresBusch inbevNorth americanஒன்றுபட்டது மாநிலங்களில்பெக்டன் டிக்கின்சன்கார்லோஸ் பிரிட்டோராக்கெட் நிறுவனங்கள்

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN), Sanofi (NYSE:SNY) - Regeneron Reports Mixed Bag On Q1 Earnings; Eylea Franchise Boosts Revenue

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN), Sanofi (NYSE:SNY) - Regeneron Reports Mixed Bag On Q1 Earnings; Eylea Franchise Boosts Revenue
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Regeneron eyleaRegeneron pharmaceuticals inc